{"product_id":"global-innovative-biologics-and-biosimilars-market-growth-status-and-outlook-2023-2029","title":"Global Innovative Biologics and Biosimilars Market Growth (Status and Outlook) 2023-2029","description":"\u003cp\u003eGlobal Innovative Biologics and Biosimilars Market Growth (Status and Outlook) 2023-2029\u003c\/p\u003e\n\n\u003cp\u003eThe global Innovative Biologics and Biosimilars market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.\u003c\/p\u003e\n\n\u003cp\u003eUnited States market for Innovative Biologics and Biosimilars is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.\u003c\/p\u003e\n\n\u003cp\u003eChina market for Innovative Biologics and Biosimilars is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.\u003c\/p\u003e\n\n\u003cp\u003eEurope market for Innovative Biologics and Biosimilars is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.\u003c\/p\u003e\n\n\u003cp\u003eGlobal key Innovative Biologics and Biosimilars players cover Roche, Amgen, AbbVie, Sanofi, Johnson \u0026amp; Johnson, Pfizer, Novo Nordisk, Eli Lilly and Novartis, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.\u003c\/p\u003e\n\n\u003cp\u003eBiologics are very specific, highly effective medicines made in living cells, and historically this was often an animal. Biologics include hormones, cytokines, growth factors, vaccines, gene and cellular therapies, fusion proteins, insulin, interferon, and monoclonal antibody (mAb) products.\u003c\/p\u003e\n\n\u003cp\u003eLPI (LP Information)' newest research report, the “Innovative Biologics and Biosimilars Industry Forecast” looks at past sales and reviews total world Innovative Biologics and Biosimilars sales in 2022, providing a comprehensive analysis by region and market sector of projected Innovative Biologics and Biosimilars sales for 2023 through 2029. With Innovative Biologics and Biosimilars sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Innovative Biologics and Biosimilars industry.\u003c\/p\u003e\n\n\u003cp\u003eThis Insight Report provides a comprehensive analysis of the global Innovative Biologics and Biosimilars landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M\u0026amp;A activity. This report also analyzes the strategies of leading global companies with a focus on Innovative Biologics and Biosimilars portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Innovative Biologics and Biosimilars market.\u003c\/p\u003e\n\n\u003cp\u003eThis Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Innovative Biologics and Biosimilars and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Innovative Biologics and Biosimilars.\u003c\/p\u003e\n\n\u003cp\u003eThis report presents a comprehensive overview, market shares, and growth opportunities of Innovative Biologics and Biosimilars market by product type, application, key players and key regions and countries.\u003c\/p\u003e\n\n\u003cp\u003eMarket Segmentation:\u003c\/p\u003e\n\n\u003cp\u003eSegmentation by type\u003cbr\u003e\nMonoclonal Antibodies\u003cbr\u003e\nInterferon\u003cbr\u003e\nInsulin\u003cbr\u003e\nVaccines\u003cbr\u003e\nOthers\u003c\/p\u003e\n\n\u003cp\u003eSegmentation by application\u003cbr\u003e\nHospital\u003cbr\u003e\nRetail Pharmacy\u003cbr\u003e\nOther\u003c\/p\u003e\n\n\u003cp\u003eThis report also splits the market by region:\u003cbr\u003e\nAmericas\u003cbr\u003e\nUnited States\u003cbr\u003e\nCanada\u003cbr\u003e\nMexico\u003cbr\u003e\nBrazil\u003cbr\u003e\nAPAC\u003cbr\u003e\nChina\u003cbr\u003e\nJapan\u003cbr\u003e\nKorea\u003cbr\u003e\nSoutheast Asia\u003cbr\u003e\nIndia\u003cbr\u003e\nAustralia\u003cbr\u003e\nEurope\u003cbr\u003e\nGermany\u003cbr\u003e\nFrance\u003cbr\u003e\nUK\u003cbr\u003e\nItaly\u003cbr\u003e\nRussia\u003cbr\u003e\nMiddle East \u0026amp; Africa\u003cbr\u003e\nEgypt\u003cbr\u003e\nSouth Africa\u003cbr\u003e\nIsrael\u003cbr\u003e\nTurkey\u003cbr\u003e\nGCC Countries\u003c\/p\u003e\n\n\u003cp\u003eThe below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.\u003cbr\u003e\nRoche\u003cbr\u003e\nAmgen\u003cbr\u003e\nAbbVie\u003cbr\u003e\nSanofi\u003cbr\u003e\nJohnson \u0026amp; Johnson\u003cbr\u003e\nPfizer\u003cbr\u003e\nNovo Nordisk\u003cbr\u003e\nEli Lilly\u003cbr\u003e\nNovartis\u003cbr\u003e\nMerck\u003cbr\u003e\nBiogen\u003cbr\u003e\nCelltrion\u003cbr\u003e\nSobi\u003cbr\u003e\n3SBIO\u003cbr\u003e\nChangchun High Tech\u003cbr\u003e\nKanghong Pharma\u003cbr\u003e\nInnovent Biologics\u003cbr\u003e\nGan\u0026amp;Lee\u003cbr\u003e\nTonghua Dongbao\u003cbr\u003e\nUnited Laboratory\u003c\/p\u003e\n\n\u003cp\u003ePlease note: The report will take approximately 2 business days to prepare and deliver.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"March, 2023 \/ 123 Pages \/ MCW16228836","offer_id":47646890819890,"sku":null,"price":4392.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-innovative-biologics-and-biosimilars-market-growth-status-and-outlook-2023-2029","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}